<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Disorders of glycogen/glucose metabolism</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Disorders of glycogen/glucose metabolism</h1>
<div class="graphic"><div class="figure"><div class="ttl">Disorders of glycogen/glucose metabolism</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Classification</td> <td class="subtitle1">Key clinical findings</td> <td class="subtitle1">Diagnosis</td> <td class="subtitle1">Therapy</td> </tr> <tr> <td>GSD 0a (MIM #240600, glycogen synthase 2 deficiency in liver)</td> <td> <ul> <li>Ketotic hypoglycemia</li> <li>No hepatomegaly</li> </ul> </td> <td> <ul> <li>Liver biopsy and enzyme testing</li> <li>DNA testing</li> </ul> </td> <td> <ul> <li>Uncooked cornstarch</li> <li>Commercial glucose polymers (eg, Glycosade)</li> <li>Liver transplantation</li> </ul> </td> </tr> <tr> <td>GSD 0b (MIM #611556, muscle glycogen synthase deficiency)</td> <td> <ul> <li>Cardiomyopathy</li> <li>Exercise intolerance</li> <li>Weakness</li> </ul> </td> <td> <ul> <li>Muscle biopsy (glycogen depletion)</li> <li>Enzyme assay</li> <li>DNA testing</li> </ul> </td> <td> <ul> <li>No specific treatment</li> </ul> </td> </tr> <tr> <td>GSD I (MIM #232200; GSD Ia, von Gierke disease, glucose-6-phosphatase deficiency; GSD Ib due to q transport defect)</td> <td> <ul> <li>Ketotic hypoglycemia</li> <li>Hepatomegaly</li> </ul> </td> <td> <ul> <li>DNA testing</li> <li>Liver biopsy</li> <li>Enzyme assay</li> </ul> </td> <td> <ul> <li>Uncooked cornstarch</li> <li>Allopurinol</li> <li>Granulocyte colony-stimulating factor (G-CSF)</li> <li>Commercial glucose polymers (eg, Glycosade)</li> <li>Liver transplantation</li> </ul> </td> </tr> <tr> <td>Lysosomal acid maltase deficiency (MIM #232300, Pompe disease, GSD II*)</td> <td> <ul> <li>Hypotonia</li> <li>Muscle weakness</li> <li>Hypertrophic cardiomyopathy</li> <li>Rhabdomyolysis</li> </ul> </td> <td> <ul> <li>Fibroblast, leukocyte, muscle, or liver enzyme assay</li> <li>DNA testing</li> </ul> </td> <td> <ul> <li>Enzyme replacement therapy</li> <li>Commercial glucose polymers (eg, Glycosade)</li> <li>Liver transplantation</li> </ul> </td> </tr> <tr> <td>Lysosome-associated membrane protein 2 (LAMP2) deficiency (MIM #300257, Danon disease, GSD IIb<sup>*</sup>)</td> <td> <ul> <li>Hypotonia</li> <li>Hypertrophic cardiomyopathy</li> <li>Rhabdomyolysis</li> </ul> </td> <td> <ul> <li>Muscle biopsy</li> <li>DNA testing</li> </ul> </td> <td> <ul> <li>No specific treatment</li> </ul> </td> </tr> <tr> <td>GSD III (MIM #232400, glycogen debrancher deficiency)</td> <td> <ul> <li>Ketotic hypoglycemia</li> <li>Hepatomegaly</li> </ul> </td> <td> <ul> <li>Fibroblast or liver enzyme assay</li> <li>DNA testing</li> </ul> </td> <td> <ul> <li>Uncooked cornstarch</li> <li>Commercial glucose polymers (eg, Glycosade)</li> <li>Liver transplantation</li> </ul> </td> </tr> <tr> <td>GSD IV (MIM #232500, glycogen branching enzyme deficiency)</td> <td> <ul> <li>Hepatomegaly</li> <li>Cirrhosis</li> <li>Rare neuromuscular presentations, such as fetal akinesia sequence, myopathy, axonal neuropathy, adult polyglucosan body disease</li> </ul> </td> <td> <ul> <li>Fibroblast, muscle, or liver biopsy</li> <li>DNA testing</li> </ul> </td> <td> <ul> <li>Commercial glucose polymers (eg, Glycosade)</li> <li>Liver transplantation</li> </ul> </td> </tr> <tr> <td>GSD V (MIM #232600, McArdle disease, muscle phosphorylase deficiency)</td> <td> <ul> <li>Fatigability</li> <li>Myoglobinuria</li> <li>Rhabdomyolysis</li> </ul> </td> <td> <ul> <li>Muscle biopsy</li> <li>Muscle enzyme assay</li> <li>DNA testing</li> </ul> </td> <td> <ul> <li>Sucrose prior to exercise</li> </ul> </td> </tr> <tr> <td>GSD VI (MIM #232700, Hers disease, liver phosphorylase deficiency)</td> <td> <ul> <li>Hepatomegaly</li> <li>Mild hypoglycemia</li> </ul> </td> <td> <ul> <li>Liver biopsy and enzyme assay</li> <li>DNA testing</li> </ul> </td> <td> <ul> <li>Commercial glucose polymers (eg, Glycosade)</li> <li>Liver transplantation</li> </ul> </td> </tr> <tr> <td>GSD VII (MIM #232800, Tarui disease, phosphofructokinase deficiency in muscle)</td> <td> <ul> <li>Fatigability</li> <li>Myoglobinuria</li> <li>Rhabdomyolysis</li> </ul> </td> <td> <ul> <li>Muscle enzyme assay</li> <li>DNA testing</li> </ul> </td> <td> <ul> <li>No specific treatment</li> </ul> </td> </tr> <tr> <td>Phosphoglycerate kinase deficiency (MIM #311800)</td> <td> <ul> <li>Hemolysis</li> <li>Fatigability</li> <li>Myoglobinuria</li> <li>CNS dysfunction</li> <li>Rhabdomyolysis</li> </ul> </td> <td> <ul> <li>Muscle/RBC enzyme assay</li> <li>DNA testing</li> </ul> </td> <td> <ul> <li>Bone marrow transplantation</li> </ul> </td> </tr> <tr> <td>GSD IX (phosphorylase kinase deficiency; IX a1, MIM #306000, formerly GSD VIII, alpha-2 subunit defect in liver; IXb, MIM #261750, beta subunit defect in liver; IXc, MIM #613027, gamma subunit defect in liver and muscle; IXd, MIM #300559, alpha subunit defect in muscle)</td> <td> <ul> <li>Hepatomegaly</li> <li>Mild hypoglycemia</li> <li>Fatigability</li> <li>Exercise intolerance</li> </ul> </td> <td> <ul> <li>Liver/muscle biopsy</li> <li>Enzyme assay</li> <li>DNA testing</li> </ul> </td> <td> <ul> <li>Commercial glucose polymers (eg, Glycosade)</li> <li>Liver transplantation</li> </ul> </td> </tr> <tr> <td>GSD X (MIM #261670, phosphoglycerate mutase deficiency)</td> <td> <ul> <li>Fatigability</li> <li>Myoglobinuria</li> <li>Exercise intolerance</li> <li>Rhabdomyolysis</li> </ul> </td> <td> <ul> <li>Muscle biopsy and enzyme assay</li> <li>DNA testing</li> </ul> </td> <td> <ul> <li>No specific treatment</li> </ul> </td> </tr> <tr> <td>GSD XI (MIM #612933; lactate dehydrogenase A [LDHA, MIM #150000] deficiency and lactate dehydrogenase B deficiency [LDHB, MIM #150100])</td> <td> <ul> <li>Fatigability</li> <li>Myoglobinuria</li> <li>Rhabdomyolysis</li> </ul> </td> <td> <ul> <li>Muscle or RBC enzyme assay</li> <li>DNA testing</li> </ul> </td> <td> <ul> <li>No specific treatment</li> </ul> </td> </tr> <tr> <td>GLUT2 deficiency (MIM #138160; Fanconi-Bickel syndrome)</td> <td> <ul> <li>Growth retardation</li> <li>Renal Fanconi syndrome</li> <li>Galactosemia</li> </ul> </td> <td> <ul> <li>Clinical features</li> <li>DNA testing</li> </ul> </td> <td> <ul> <li>Frequent, small meals</li> <li>Uncooked cornstarch or nocturnal enteral nutrition</li> <li>Electrolytes, carnitine, and vitamin D as needed</li> <li>Restriction of galactose</li> </ul> </td> </tr> <tr> <td>GSD XII (MIM #611881, aldolase A deficiency)</td> <td> <ul> <li>Hemolysis</li> <li>Jaundice</li> <li>Myoglobinuria</li> <li>Muscle weakness</li> <li>Fatigability</li> <li>Rhabdomyolysis</li> </ul> </td> <td> <ul> <li>Muscle or RBC enzyme assay</li> <li>DNA testing</li> </ul> </td> <td> <ul> <li>No specific treatment</li> </ul> </td> </tr> <tr> <td>GSD XIII (MIM #612932, beta-enolase deficiency in muscle)</td> <td> <ul> <li>Exercise intolerance</li> <li>Increased CPK</li> <li>Rhabdomyolysis</li> </ul> </td> <td> <ul> <li>Muscle biopsy</li> <li>Enzyme assay</li> <li>DNA testing</li> </ul> </td> <td> <ul> <li>No specific treatment</li> </ul> </td> </tr> <tr> <td>GSD XIV (MIM #612934, phosphoglucomutase 1 deficiency in muscle)</td> <td> <ul> <li>Exercise intolerance</li> <li>Myoglobinuria</li> <li>Increased CPK</li> <li>Rhabdomyolysis</li> <li>Myoglobinuria</li> </ul> </td> <td> <ul> <li>Muscle biopsy</li> <li>Enzyme assay</li> <li>DNA testing</li> </ul> </td> <td> <ul> <li>No specific treatment</li> </ul> </td> </tr> <tr> <td>GSD XV (MIM #613507, glycogenin 1 deficiency in muscle)</td> <td> <ul> <li>Muscle weakness</li> <li>Arrhythmias</li> </ul> </td> <td> <ul> <li>Muscle biopsy (glycogen depletion)</li> <li>DNA testing</li> </ul> </td> <td> <ul> <li>No specific treatment</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes">GSD: glycogen storage disease; CNS: central nervous system; RBC: red blood cell; GLUT2: glucose transporter 2; CPK: creatine phosphokinase.<br/>
	
	* These diseases were originally classified as GSDs. It was subsequently recognized that the accumulation of glycogen in lysosomes seen in these diseases is due to defective lysosomal metabolism rather than energy deficiency from glycogen/glucose metabolism. Thus, they are considered both GSDs and lysosomal storage diseases.</div><div id="graphicVersion">Graphic 54417 Version 16.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
